IP Library Granted Patent US 9,708,338
Granted Patent B2
US 9,708,338 · App. 15/076,728 · Granted Jul 18, 2017

Aromatic heterocyclylamine derivative having TRPV4-inhibiting activity

Inventors: Akira Yukimasa (Osaka, JP); Naoki Tsuno (Osaka, JP); Motohiro Fujiu (Osaka, JP); Hiroki Yamaguchi (Osaka, JP); Hiromi Kudo (Osaka, JP); Tatsuhiko Ueno (Osaka, JP); Yusuke Ichihashi (Osaka, JP); Takatsugu Inoue (Osaka, JP); Shinji Suzuki (Osaka, JP)
Assignee: SHIONOGI & CO., LTD.
C07D491/08C07D417/14C07D471/04C07D471/08C07D487/04C07D491/10C07D491/107C07D498/08C07D498/10C07D513/08
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,708,338
App. No.
15/076,728
Granted
Jul 18, 2017
Kind
B2
Abstract

The present invention is related to a compound represented by formula (I) wherein —X— is —NH— or —S—; —Z— is —O— or —S—; R 3 , R 5 and R 6 are each independently a hydrogen atom, substituted or unsubstituted alkyl, or the like; R 7 is a cyano, substituted or unsubstituted amino, or the like; R 7′ is each independently a halogen; b is 0 or 1; or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising thereof.

Claims (50)

1. A compound of formula (I):

wherein:

—X— is —NH— or —S—;

—Z— is —O— or —S—;

R 3 , R 5 and R 6 are each independently a hydrogen atom, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkynyloxy, substituted or unsubstituted amino, substituted or unsubstituted carbamoyl, substituted or unsubstituted aromatic carbocyclyl, substituted or unsubstituted non-aromatic carbocyclyl, substituted or unsubstituted aromatic heterocyclyl, or substituted or unsubstituted non-aromatic heterocyclyl;

R 7 is a cyano, substituted or unsubstituted amino, substituted or unsubstituted alkyl (with the proviso that unsubstituted methyl is excluded), substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkynyloxy, substituted or unsubstituted alkylcarbonyl, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted sulfamoyl, substituted or unsubstituted aromatic carbocyclyl carbonyl, substituted or unsubstituted non-aromatic carbocyclylcarbonyl, substituted or unsubstituted aromatic heterocyclyl carbonyl, or substituted or unsubstituted non-aromatic heterocyclylcarbonyl;

R 7′ is each independently a halogen;

b is 0 or 1;

or a pharmaceutically acceptable salt thereof.

2. The compound according to claim 1 ,

wherein

—X— is —S—;

—Z— is —S—,

or a pharmaceutically acceptable salt thereof.

3. The compound according to claim 2 ,

wherein

R 7 is a group represented by the following formula:

wherein

ring B is non-bridged non-aromatic heterocyclyl, or bridged non-aromatic heterocyclyl;

R 8 is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aromatic carbocyclyl, or substituted or unsubstituted aromatic heterocyclyl;

R 8a is each independently halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, or substituted or unsubstituted alkynyl;

c is 0, 1, or 2;

or a pharmaceutically acceptable salt thereof.

4. The compound according to claim 3 ,

wherein

R 7 is a group represented by the following formula:

wherein

m is 2;

two R 9 groups may be taken together to form (C2-C4) bridge;

the carbon atoms that consist of the bridge are each independently substituted with the substituent selected from R a ;

R a is a hydrogen atom, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, or substituted or unsubstituted alkynyl;

R 8 is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aromatic carbocyclyl, or substituted or unsubstituted aromatic heterocyclyl;

or a pharmaceutically acceptable salt thereof.

5. A compound of formula (III):

wherein

R 7 is substituted or unsubstituted non-aromatic heterocyclylcarbonyl;

D is a group represented by the following formula:

wherein

R 4′ is a hydrogen atom, or substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, or substituted or unsubstituted alkynyl;

R 5′ is a hydrogen atom, or substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, or substituted or unsubstituted alkynyl;

—X— is —NH— or —S—;

R 3 is each independently a hydrogen atom, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkynyloxy, substituted or unsubstituted amino, substituted or unsubstituted carbamoyl, substituted or unsubstituted aromatic carbocyclyl, substituted or unsubstituted non-aromatic carbocyclyl, substituted or unsubstituted aromatic heterocyclyl, or substituted or unsubstituted non-aromatic heterocyclyl;

R 7′ is each independently a halogen;

b is 0 or 1;

or a pharmaceutically acceptable salt thereof.

6. A pharmaceutical composition containing the compound according to claim 1 , or a pharmaceutically acceptable salt thereof.

7. A pharmaceutical composition containing the compound according to claim 2 , or a pharmaceutically acceptable salt thereof.

8. A pharmaceutical composition containing the compound according to claim 3 , or a pharmaceutically acceptable salt thereof.

9. A pharmaceutical composition containing the compound according to claim 4 , or a pharmaceutically acceptable salt thereof.

10. A pharmaceutical composition containing the compound according to claim 5 , or a pharmaceutically acceptable salt thereof.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 22, 2016
From: YUKIMASA, AKIRA; TSUNO, NAOKI; FUJIU, MOTOHIRO; YAMAGUCHI, HIROKI; KUDO, HIROMI; UENO, TATSUHIKO; ICHIHASHI, YUSUKE; INOUE, TAKATSUGU; SUZUKI, SHINJI
To: SHIONOGI & CO., LTD.
Reel/Frame 038058/0962 →
Priority Claims (2)
JP 2013-198310 · Sep 25, 2013 · national
JP 2014-112826 · May 30, 2014 · national
Continuity (2)
Continuation PCTJP2014075178 · Sep 24, 2014
Related Publication 20160200721A1 · Jul 14, 2016